Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.

LODDO, ROBERTA
2014-01-01

Abstract

Novel riminophenazine derivatives, characterized by the presence of the basic and cumbersome quinolizidinylalkyl and pyrrolizidinylethyl moieties, have been synthesized and tested (Rema test) against Mycobacterium tuberculosis H37Rv and H37Ra, and six clinical isolates of Mycobacterium avium and Mycobacterium tuberculosis. Most compounds exhibited potent activity against the tested strains, resulting more active than clofazimine, isoniazid and ethambutol. The best compounds (4, 5, 12 and 13) exhibited a MIC in the range 0.82-0.86μM against all strains of Mycobacterium tuberculosis and, with the exception of 4 a MIC around 3.3μM versus M. avium. The corresponding values for clofazimine (CFM) were 1.06 and 4.23μM, respectively. Cytotoxicity was evaluated against three cell lines and compound 4 displayed a selectivity index (SI) versus the human cell line MT-4 comparable with that of CFM (SI=5.23 vs 6.4). Toxicity against mammalian Vero 76 cell line was quite lower with SI=79.
2014
Antitubercular activity; Clinical isolates of Mycobacterium tuberculosis; Mycobacterium avium; Mycobacterium tuberculosis; Quinolizidinyl- and pyrrolizidinyl-alkyliminophenazine derivatives
Files in This Item:
File Size Format  
Bioorganic 6837-6845 ( 2014).pdf

Solo gestori archivio

Type: versione editoriale
Size 692.83 kB
Format Adobe PDF
692.83 kB Adobe PDF & nbsp; View / Open   Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie